Articles

BeiGene inks deals for Zymeworks antibodies and platforms

The agreements cover ZW25 and ZW49, two HER2-targeted bispecific antibodies, and Zymeworks' Azymetric and EFECT platforms
Written byKelsey Kaustinen
| 3 min read

VANCOUVER, BEIJING & CAMBRIDGE, Mass.—Zymeworks is going transcontinental with its latest partnership, having signed a series of agreements with China-based BeiGene Ltd. Among the agreements is a strategic collaboration for the clinical development and commercialization of ZW25 and ZW49, Zymeworks' investigational HER2-targeted bispecific antibodies, as well as a deal that provides BeiGene with a license to Zymeworks' Azymetric and EFECT platforms for the global development and commercialization of up to three additional bispecific antibodies.

“Partnering with BeiGene was a key component of our development and commercialization strategy for ZW25 and ZW49,” said Dr. Ali Tehrani, president and CEO of Zymeworks. “This collaboration allows Zymeworks to leverage BeiGene’s resources and expertise to accelerate the development of our most advanced product candidates and broaden our reach globally including in a key region of the world.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.